In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.

University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer’s disease treatments by targeting one of the brain’s most important genes for risk and resilience.